{
"info": {
"nct_id": "NCT05380882",
"official_title": "A Phase I Study of TQB2930 Injection in Patients With Advanced Cancers",
"inclusion_criteria": "* 1 Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study;\n* 2 Male or female patient 18 to 75 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and life expectancy ≥12 weeks;\n* 3 Histologically or cytologically confirmed, locally advanced tumors, Priority will be given to subjects with HER2 positive solid tumor;\n* 4 Malignant tumor that failed from standard treatment or had no standard treatment;\n* 5 According to the RECIST 1.1 standard, patient with at least one evaluable lesion;\n* 6 The main organs function well;\n* 7 Male or female patient had no plans to become pregnant and voluntarily took effective contraceptive measures from agree with the study to at least 6 months after the last dose of study drug.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
"exclusion_criteria": "* 1 Concurrent secondary malignancy. or other malignancy with no evidence of disease for more than 3 years;\n* 2 History of uncontrolled intercurrent illness;\n* 3 Major surgical procedure, radiotherapy, chemotherapy, or immunotherapy within 4 weeks prior to first dose;\n* 4 Patients with known symptomatic brain metastases;\n* 5 Receiving any other investigational agent within 4 weeks before first dose;\n* 6 Unstable or serious concurrent medical conditions, as assessed by the Investigators, that would substantially increase the risk-benefit ratio of participating in the study.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* 1 Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study;",
"criterions": [
{
"exact_snippets": "Evidence of a personally signed and dated informed consent document",
"criterion": "informed consent document",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "indicating that the patient has been informed of all pertinent aspects of the study",
"criterion": "patient informed of study aspects",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* 2 Male or female patient 18 to 75 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and life expectancy ≥12 weeks;",
"criterions": [
{
"exact_snippets": "Male or female patient",
"criterion": "gender",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "18 to 75 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
},
{
"operator": "<=",
"value": 75,
"unit": "years"
}
]
}
}
]
},
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
]
},
{
"exact_snippets": "life expectancy ≥12 weeks",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* 3 Histologically or cytologically confirmed, locally advanced tumors, Priority will be given to subjects with HER2 positive solid tumor;",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed",
"criterion": "tumor confirmation method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "locally advanced tumors",
"criterion": "tumor stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "locally advanced"
}
]
},
{
"exact_snippets": "HER2 positive solid tumor",
"criterion": "HER2 status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "positive"
}
]
}
]
},
{
"line": "* 4 Malignant tumor that failed from standard treatment or had no standard treatment;",
"criterions": [
{
"exact_snippets": "Malignant tumor",
"criterion": "malignant tumor",
"requirements": [
{
"requirement_type": "treatment response",
"expected_value": "failed from standard treatment or had no standard treatment"
}
]
}
]
},
{
"line": "* 5 According to the RECIST 1.1 standard, patient with at least one evaluable lesion;",
"criterions": [
{
"exact_snippets": "RECIST 1.1 standard, patient with at least one evaluable lesion",
"criterion": "evaluable lesion",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
}
]
}
]
},
{
"line": "* 6 The main organs function well;",
"criterions": [
{
"exact_snippets": "main organs function well",
"criterion": "main organ function",
"requirements": [
{
"requirement_type": "functionality",
"expected_value": "well"
}
]
}
]
},
{
"line": "* 7 Male or female patient had no plans to become pregnant and voluntarily took effective contraceptive measures from agree with the study to at least 6 months after the last dose of study drug.",
"criterions": [
{
"exact_snippets": "Male or female patient",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": [
"male",
"female"
]
}
]
},
{
"exact_snippets": "no plans to become pregnant",
"criterion": "pregnancy plans",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": false
}
]
},
{
"exact_snippets": "voluntarily took effective contraceptive measures",
"criterion": "contraceptive measures",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": true
}
]
},
{
"exact_snippets": "from agree with the study to at least 6 months after the last dose of study drug",
"criterion": "duration of contraceptive measures",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "from agree with the study to at least 6 months after the last dose of study drug"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 75 Years",
"criterions": [
{
"exact_snippets": "maximum age of 75 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* 1 Concurrent secondary malignancy. or other malignancy with no evidence of disease for more than 3 years;",
"criterions": [
{
"exact_snippets": "Concurrent secondary malignancy",
"criterion": "concurrent secondary malignancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "other malignancy with no evidence of disease for more than 3 years",
"criterion": "other malignancy",
"requirements": [
{
"requirement_type": "disease evidence",
"expected_value": false
},
{
"requirement_type": "disease-free duration",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "years"
}
}
]
}
]
},
{
"line": "* 2 History of uncontrolled intercurrent illness;",
"criterions": [
{
"exact_snippets": "History of uncontrolled intercurrent illness",
"criterion": "uncontrolled intercurrent illness",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* 3 Major surgical procedure, radiotherapy, chemotherapy, or immunotherapy within 4 weeks prior to first dose;",
"criterions": [
{
"exact_snippets": "Major surgical procedure, radiotherapy, chemotherapy, or immunotherapy within 4 weeks prior to first dose",
"criterion": "major surgical procedure",
"requirements": [
{
"requirement_type": "time since procedure",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "Major surgical procedure, radiotherapy, chemotherapy, or immunotherapy within 4 weeks prior to first dose",
"criterion": "radiotherapy",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "Major surgical procedure, radiotherapy, chemotherapy, or immunotherapy within 4 weeks prior to first dose",
"criterion": "chemotherapy",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "Major surgical procedure, radiotherapy, chemotherapy, or immunotherapy within 4 weeks prior to first dose",
"criterion": "immunotherapy",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* 4 Patients with known symptomatic brain metastases;",
"criterions": [
{
"exact_snippets": "known symptomatic brain metastases",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "symptomatic",
"expected_value": true
},
{
"requirement_type": "known",
"expected_value": true
}
]
}
]
},
{
"line": "* 5 Receiving any other investigational agent within 4 weeks before first dose;",
"criterions": [
{
"exact_snippets": "Receiving any other investigational agent within 4 weeks before first dose",
"criterion": "investigational agent",
"requirements": [
{
"requirement_type": "time since last dose",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* 6 Unstable or serious concurrent medical conditions, as assessed by the Investigators, that would substantially increase the risk-benefit ratio of participating in the study.",
"criterions": [
{
"exact_snippets": "Unstable or serious concurrent medical conditions",
"criterion": "concurrent medical conditions",
"requirements": [
{
"requirement_type": "severity",
"expected_value": [
"unstable",
"serious"
]
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}